Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

NCT03381729 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class

Stopped Based upon overall strategic objectives within the broader intrathecal clinical development program, Novartis Gene Therapies decided to terminate the study early.

Conditions

Interventions

Sponsor

Novartis Gene Therapies